- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07596810
Ketamine Added to Quadratus Lumborum Block for Pain Relief After Infant Pyeloplasty (KETA-QLB)
Ketamine As Adjuvant to Bupivacaine in Ultrasound Guided Quadratus Lumborum Block for Infants Undergoing Open Pyeloplasty
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
Postoperative pain management in infants undergoing open pyeloplasty remains challenging because opioid use may be associated with adverse effects, including respiratory depression, nausea, vomiting, and delayed recovery. Regional anesthesia techniques, including ultrasound-guided quadratus lumborum (QL) block, may improve postoperative analgesia and reduce opioid requirements.
Ketamine has analgesic properties through N-methyl-D-aspartate (NMDA) receptor antagonism and has been investigated as an adjuvant to local anesthetics in regional anesthesia. However, evidence regarding its use as an adjuvant in ultrasound-guided QL block in infants undergoing pyeloplasty is limited.
This prospective randomized study aims to evaluate the effectiveness of adding ketamine to bupivacaine in ultrasound-guided QL block for infants undergoing open pyeloplasty. Forty infants aged 0-12 months scheduled for elective open pyeloplasty are randomized into two groups. One group receives ultrasound-guided QL block using bupivacaine 0.25% (0.5 mL/kg) combined with ketamine hydrochloride (1 mg/kg), while the control group receives bupivacaine 0.25% (0.5 mL/kg) alone.
The primary outcome measure is postoperative pain assessed using the CRIES pain scale during the first 24 hours after surgery. Secondary outcome measures include time to first rescue opioid administration, total postoperative opioid consumption, length of hospital stay, and occurrence of adverse events or complications.
This study seeks to determine whether ketamine may improve postoperative analgesia and reduce opioid requirements when used as an adjuvant to bupivacaine in pediatric regional anesthesia.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 4
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Alexandria, Egipto
- Alexandria University
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Infants aged 0 to 12 months
- Scheduled for elective open pyeloplasty
- Eligible for ultrasound-guided quadratus lumborum block
- Parent or legal guardian able to provide informed consent
Exclusion Criteria:
- Congenital heart disease
- Prematurity
- Mechanical ventilation dependence
- Contraindications to regional anesthesia
- Coagulopathy or bleeding disorders
- Local infection at the injection site
- Known allergy or hypersensitivity to ketamine, bupivacaine, or study medications
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Ketamine + Bupivacaine QL Block
Participants receive ultrasound-guided quadratus lumborum block using ketamine hydrochloride (1 mg/kg) combined with bupivacaine 0.25% (0.5 mL/kg) during open pyeloplasty.
|
Ketamine hydrochloride (1 mg/kg) added to bupivacaine 0.25% (0.5 mL/kg) administered by ultrasound-guided quadratus lumborum block during open pyeloplasty.
|
|
Comparador activo: Bupivacaine QL Block
Participants receive ultrasound-guided quadratus lumborum block using bupivacaine 0.25% (0.5 mL/kg) alone during open pyeloplasty.
|
Bupivacaine 0.25% (0.5 mL/kg) administered by ultrasound-guided quadratus lumborum block during open pyeloplasty.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Postoperative Pain Assessed by CRIES Pain Scale by the end of 24 hours after surgery
Periodo de tiempo: 24 hours after surgery
|
Postoperative pain severity assessed using the CRIES pain scale during the first 24 hours after surgery.
Higher scores indicate greater pain severity.
|
24 hours after surgery
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Time to First Rescue Opioid Administration
Periodo de tiempo: 24 hours after surgery
|
Time elapsed from completion of surgery to first administration of rescue opioid analgesia (intravenous fentanyl).
|
24 hours after surgery
|
|
Total Postoperative Opioid Consumption
Periodo de tiempo: 24 hours after surgery
|
Total postoperative fentanyl consumption during the postoperative observation period.
|
24 hours after surgery
|
|
Length of Hospital Stay
Periodo de tiempo: Until hospital discharge (approximately 1-3 days)
|
Duration of hospitalization measured in days following surgery.
|
Until hospital discharge (approximately 1-3 days)
|
|
Occurrence of Postoperative Complications
Periodo de tiempo: 24 hours after surgery until discharge
|
Incidence of adverse events and complications related to the intervention or postoperative period.
|
24 hours after surgery until discharge
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Dolor
- Manifestaciones neurológicas
- Complicaciones Postoperatorias
- Procesos Patológicos
- Condiciones Patológicas, Signos y Síntomas
- Signos y síntomas
- Dolor Postoperatorio
- Displasia renal multicítica, bilateral
- Químicos orgánicos
- Hidrocarburos
- Ciclohexanos
- Cicloparafinas
- Hidrocarburos, alicíclicos
- Hidrocarburos, cíclico
- Aniluros
- Amidas
- Compuestos anilina
- Amina
- Bupivacaína
- Ketamina
Otros números de identificación del estudio
- 0307848
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .